Depending on the cancer type, cancer stage, and presence of metastasis, 28–100% of the cancer patients can have aberrant levels of sPLA2 that are in average 6–8 times higher in the tumor compartment than in serum [13–15]. Here, PLA2G2A is linked to cancer.